medicina58巻3号

2021年03月発行

特集 いまさら聞けない！ 肝胆膵疾患—みなさんのギモンに答えます 肝機能異常をみたら

B型肝炎・C型肝炎治療薬による治療中の副作用と治療終了後の留意点

著者： 中川美奈¹² 朝比奈靖浩¹³

所属機関： ¹東京医科歯科大学消化器内科 ²東京医科歯科大学統合教育機構 ³東京医科歯科大学肝臓病態制御学

ページ範囲：P.420 - P.423

　慢性肝炎は自覚症状に乏しく，予測される副作用，合併症，リスク因子に十分留意することが重要であり，適切な患者指導および医療介入により無症状の慢性肝疾患患者の予後を改善させることは，臨床医の腕の見せ所であると同時に，限られた医療資源の有効活用のためにも重要である．

参考文献

1）日本肝臓学会 肝炎診療ガイドライン作成委員会（編）：B型肝炎治療ガイドライン（第3.3版），2021　https://www.jsh.or.jp/files/uploads/HBV_GL_ver3.3.pdf（2021年1月閲覧）

2）Tamori A, et al：Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 17：123-129, 2010

3）Marcellin P, et al：Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48：750-758, 2008

4）Tanaka M, et al：Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol 49：470-480, 2014

5）Fung J, et al：Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol 29：428-434, 2014

6）Rodríguez-Nóvoa S, et al：Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 24：1064-1066, 2010

7）Lee WA, et al：Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49：1898-1906, 2005

8）Kearney BP, et al：Tenofovir disoproxil fumarate；Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43：595-612, 2004

9）日本肝臓学会 肝炎診療ガイドライン作成委員会（編）：C型肝炎治療ガイドライン（第8版），2020　http://www.jsh.or.jp/files/uploads/HCV_GL_ver8_20201005.pdf（2021年1月閲覧）

10）Nagata H, et al：Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67：933-939, 2017

11）Yasui Y, et al：Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol Res 48：1131-1139, 2018

12）Ooka Y, et al：Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Hepatol Int 12：523-530, 2018

13）Toyoda H, et al：Impact of previously cured hepatocellular carcinoma（HCC）on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther 48：664-670, 2018

14）Aleman S, et al：A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57：230-236, 2013

15）Toyoda H, et al：Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 30：1183-1189, 2015

16）Ito K, et al：LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 56：1448-1456, 2012

17）Yamasaki K, et al：Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 60：1563-1570, 2014

18）Sasaki R, et al：Serum wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis c after sustained virological response. PLoS One 10：e0129053, 2015

19）Nagata H, et al：Serial measurement of wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int 10：956-964, 2016

20）Nakagawa M, et al：Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol 55：990-999, 2020

21）Shirabe K, et al：Mac-2 binding protein glycan isomer（M2BPGi）is a new serum biomarker for assessing liver fibrosis；More than a biomarker of liver fibrosis. J Gastroenterol 53：819-826, 2018

22）Sharma UC, et al：Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110：3121-3128, 2004